摘要
目的观察健脾柔肝方联合替吉奥胶囊治疗中晚期原发性肝癌患者的临床疗效。方法将55例中晚期原发性肝癌患者随机分为对照组25例和治疗组30例,对照组口服替吉奥胶囊化疗,治疗组在对照组的基础上口服健脾柔肝方加减,每日1剂。两组均以21天为1个疗程,共4个疗程。治疗前后比较两组患者中医症状评分、生活质量评分、肝脏瘤体大小。治疗后评价临床疗效、中医证候疗效、生活质量疗效及毒副反应,随访治疗后1年内生存情况。结果治疗组临床疗效的客观有效率为30.00%,临床受益率为83.33%;对照组客观有效率为28.00%,临床受益率为76.00%,两组客观有效率和临床受益率比较差异均无统计学意义(P>0.05)。治疗组中医证候疗效和生活质量总有效率明显高于对照组(P<0.05)。治疗后治疗组各项症状积分较治疗前明显降低(P<0.05),治疗后治疗组纳差、乏力、腹胀、便溏积分均明显低于对照组(P<0.05)。两组治疗后生活质量评分均较治疗前明显升高,肿瘤大小明显减小(P<0.05),治疗后治疗组生活质量评分明显高于对照组(P<0.05)。治疗组白细胞减少、血小板减少、口腔炎、周围神经毒性发生例数均明显少于对照组(P<0.05)。两组生存曲线差异有统计学意义(P<0.05)。结论健脾柔肝方联合替吉奥胶囊可以改善中晚期原发性肝癌患者的临床症状,提高生活质量,降低化疗毒副反应,延长生存期。
Objective To observe the clinical effects of Jianpi Rougan Fang combined with Tegafur Gimeracil Oteracil Potassium capsule in the treatment of 30 patients with primary hepatic carcinoma in the middle and advanced stage. Methods Fifty-five patients with primary hepatic carcinoma in the middle and advanced stage were divided into the control group（ 25 cases） and the treatment group（ 30 cases）. Both groups took Tegafur Gimeracil Oteracil Potassium capsule for chemotherapy. The treatment group also took modified Jianpi Rougan Fang,one dose daily.Twenty-one days were considered as a treatment course,and both groups were given four treatment courses in all.Scores of Chinese medical symptom,quality of life,and size of hepatic tumors in two groups were compared before and after the treatment. The clinical effects,curative effects of Chinese medical symptom,quality of life,and toxic and side effects were evaluated after the treatment. The survival situation within one year after the treatment was also followed-up. Results The objective response rate of clinical effects and the clinical beneficial rate were 30. 00%and 83. 33% in the treatment group,but 28. 00% and 76. 00% in the control group,respectively,with no significant difference between the two groups（ P〉0. 05）. In the treatment group,the total effective rates of curative effects of Chinese medical symptom and quality of life were significantly higher than those in the control group（ P〈0. 05）. After the treatment,scores of symptoms in the treatment group were significantly lower than those before the treatment（ P〈0. 05）. After the treatment,scores of poor appetite,fatigue,abdominal distension and loose stool in the treatment group were significantly lower than those in the control group（ P〈0. 05）. After the treatment in both groups,KPS score were significantly higher and the tumor size significantly decreased than those before the treatment（ P〈0. 05）. After the treatment,score of the quality of life in the treatment group was significantly higher than that in the control group（ P〈0. 05）. In the treatment group,cases with leukopenia,thrombocytopenia,stomatitis,and peripheral neurovirulence were significantly less than those in the control group（ P〈0. 05）. There was statistically significant difference in survival curve between the two groups（ P〈0. 05）. Conclusion Jianpi Rougan Fang combined with Tegafur Gimeracil Oteracil Potassium capsule may improve clinical symptoms and quality of life,reduce toxic and side effects of chemotherapy,and prolong survival time of patients with primary hepatic carcinoma in the middle and advanced stage.
出处
《中医杂志》
CSCD
北大核心
2016年第8期677-681,共5页
Journal of Traditional Chinese Medicine
基金
浙江省中医药科技计划(2011ZA095)
关键词
原发性肝癌
健脾柔肝方
替吉奥胶囊
生活质量
毒副反应
primary hepatic carcinoma
Jianpi Rougan Fang（健脾柔肝方）
Tegafur Gimeracil Oteracil Potassium capsule
quality of life
toxic and side effects
